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ABSTRACT
Background and Objectives: The prevalence of arthritis, which is often treated with celecoxib, is high in patients with cor-
onary artery disease. Furthermore, celecoxib has been reported to reduce restenosis after coronary stenting by inhibiting ex-
pression of the proto-oncogene Akt. A concern is that celecoxib increases thrombogenicity by inhibiting the synthesis of 
prostacyclin in endothelial cells. However, it is not known whether the administration of celecoxib will attenuate the anti-
platelet effects of aspirin and clopidogrel, which are used after stenting. We addressed this gap in our knowledge. Subjects and 
Methods: We recruited healthy volunteers (n=40) and randomized them into five subgroups (n=8 for each group: aspirin, 
celecoxib, aspirin+celecoxib, aspirin+clopidogrel, and aspirin+clopidogrel+celecoxib). Each subject received their medica-
tions for 6 days and blood samples were taken on day 0 and day 7. Celecoxib (200 mg twice a day), and/or aspirin (100 mg dai-
ly), and/or clopidogrel (75 mg daily) were administered. We compared platelet function among subgroups using light trans-
mittance aggregometry and arachidonic acid metabolite assays. Results: Celecoxib treatment alone did not significantly affect 
platelet aggregation. The reduction in adenosine diphosphase (ADP)-induced platelet aggregation by aspirin+clopidogrel 
was not affected by addition of celecoxib (31.3±6.9% vs. 32.4±12.2%, p=0.83). Inhibition of collagen-induced platelet aggre-
gation by aspirin+clopidogrel was not affected by addition of celecoxib (47.6±13.4% vs. 51.6±3.7%, p=0.69). Drug-induced 
changes in prostacyclin and thromboxane levels did not differ among treatment groups. Conclusion: Celecoxib treatment 
does not interfere with the antiplatelet effects of aspirin or clopidogrel, suggesting that celecoxib can be safely administered in 
combination with dual antiplatelet therapy in patients with coronary stenting without increased thrombogenicity. (Korean 
Circ J 2010;40:321-327)
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Introduction
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibi-
tor, has been widely used to manage patients with osteoar-
thritis and rheumatoid arthritis. It causes less gastric irrita-
tion compared to nonselective COX inhibitors.
1) High dose 
celecoxib reduced the number of colorectal polyps in patients 
with familial adenomatous polyposis.
2) Moreover, we recent-
ly reported that celecoxib reduced restenosis and target lesion 
revascularization after coronary stenting.
3)
Recent clinical studies, however, have suggested that COX-
2 inhibitors increase the incidence of cardiovascular events.
4-6) 
Rofecoxib was associated with adverse cardiovascular events 
in a colorectal adenoma chemoprevention trial, and it was wi-
thdrawn from the world market.
4) However, the results of clin-
ical studies regarding celecoxib are controversial. Celecoxib 
was found to dose-dependently increase the composite end 
point of death from cardiovascular causes, myocardial infarc-
tion, stroke, or heart failure in the Adenoma Prevention with 
Celebrex (APC) trial.
5) Two other large studies, Prevention of 322   Celecoxib on Dual Antiplatelet
Spontaneous Adenomatous Polyps and Alzheimer’s Disease 
Anti-inflammatory Prevention Trial (ADAPT), did not show 
increased cardiovascular risk associated with celecoxib.
7)8)
Dual antiplatelet therapy with aspirin and clopidogrel is es-
sential for at least one year in patients with coronary stenting, 
especially those with drug-eluting stents. It is the most impor-
tant treatment for preventing a fatal complication, stent th-
rombosis.
9)10) Since the number of patients with ischemic he-
art disease is increasing, and many of them are elderly and 
have arthritis, there are more and more candidates for treat-
ment with both celecoxib and antiplatelet agents.
11) However, 
the safety profile of celecoxib with concomitant administra-
tion of aspirin and clopidogrel has not been evaluated. We con-
ducted the current study to evaluate 1) whether celecoxib can 
be used safely with antiplatelet agents, and 2) whether celecox-
ib interferes with the antiplatelet activity of aspirin and clopi-
dogrel. 
Subjects and Methods
Subjects
Healthy volunteers including both men and women 20 to 
30 years of age were recruited for this study. Subjects were 
proved to have no abnormalities on physical examination, 12-
lead electrocardiogram, and routine laboratory tests. Subjects 
with a history of cardiovascular disease, or hemostatic disor-
der, and hypersensitivity to NSAIDs and clopidogrel, were ex-
cluded. Women with childbearing potential were tested for 
pregnancy, and women with a positive test result were exclud-
ed. Others were excluded if they were smokers, chronic drink-
ers or overweight (exceeding 20% of standard body weight). 
Subjects had to abstain from alcohol, beverages containing 
caffeine, and other drugs beginning one week before the study. 
The study was approved by the review board of Seoul Na-
tional University Hospital. Written and informed consent was 
obtained from all volunteers before enrollment in the study.
Study design
We designed a single-center, open label, parallel-group and 
randomized study. Young healthy volunteers (n=40) were ran-
domized into 5 groups: celecoxib only (CCX), aspirin only 
(ASA), celecoxib+aspirin (CCX+ASA), aspirin+clopidogrel 
(CCX+CPD), and celecoxib+aspirin+clopidogrel group (CCX+ 
ASA+CPD). Screening tests were performed 3 days before the 
initiation of the study. A celecoxib (Celebrex
®, Pfizer Korea, 
Seoul, Korea) dose of 200 mg twice a day was chosen since 
this is the usual dose in clinical practice for treating arthritis 
and pain. Aspirin (Rhonal
®, Kun-Wha Pharmaceuticals, Se-
oul, Korea) 100 mg daily, and/or clopidogrel (Plavix
®, Sanofi-
Aventis, Seoul, Korea) 75 mg daily were used because they are 
the standard doses for treating patients with ischemic heart 
disease. Each subject received their assigned medications for 
six consecutive days. Blood samples were collected at day 0 
(pre) and day 7 (post) for assessment of platelet aggregation. 
Urine samples were collected at the same time to evaluate 
prostacyclin and thromboxane levels.
Whole blood samples were drawn into four standard sodi-
um citrate containing tubes. Samples were centrifuged at 1,200 
rpm for 2 minutes and 30 seconds. Platelet aggregation was 
induced by adenosine 5’-diphosphate (adenosine diphosph-
ase, ADP) or collagen. It was measured using a Chronolog Lu-
mi-Aggregometer (model 560-Ca, Chrono-log Corp., Haver-
town, PA, USA). The extent of platelet aggregation in samples 
was expressed by the maximum increase in light transmit-
tance compared to baseline values. 
Urine 6-keto PGF1α, a stable metabolite of prostaglandin I2 
(PGI2), was measured as described in previous studies.
12)13) 
Urine samples were centrifuged to remove any precipitates. 
Correlate-EIA
TM Immunoassay kits (Assay Designs, Inc., Ann 
Arbor, MI, USA) were used to measure urine levels of 6-keto 
PGF1α. Values obtained using the kit were adjusted by VAGUE. 
the urine creatinine level of each subject. Urine samples were 
also used to measure urinary 11-dehydro-TXB2, which is a ma-
jor metabolite of TXB2. Correlate-EIA
TM Immunoassay kits 
(Assay Designs, Inc., Ann Arbor, MI, USA) designed for uri-
nary 11-dehydro-TXB2 were used.
Statistics
Platelet aggregation results are presented as means and st-
andard deviations. Changes from baseline values were calcu-
lated to detect the average differences in the platelet aggrega-
tion for each treatment group. The Wilcoxon rank sum test 
was used to analyze for between group differences. Results for 
urinary 6-keto PGF1α were calculated to show changes from 
baseline values. The Mann-Whitney test was performed to 
show whether any differences in prostacyclin between groups 
was statistically significant. Statistical Package for the Social 
Sciences (SPSS) software (Version 12.0 for Windows, SPSS 
Inc, Chicago, IL, USA) was used for statistical analysis. A 
p<0.05 was considered to indicate statistical significance.
Results
Forty healthy subjects who met the inclusion criteria were 
screened and randomized. The baseline characteristics of sub-
jects are described in Table 1. The ages of volunteers ranged 
from 21 to 35 years. Mean ages among the treatment groups 
were similar while the distribution of gender varied. All sub-
jects completed the study, and there were no notable adverse 
events during the study. 
Platelet aggregation
Fig. 1A shows ADP-induced platelet aggregation measured 
before and after each treatment. The CCX group showed no Wonjae Lee, et al.   323
significant change in platelet aggregation after treatment (pre-
treatment 86.9±11.0% vs. post-treatment 74.6±18.5%, p= 
0.29). ASA and ASA+CPD groups showed significantly re-
duced ADP-induced platelet aggregation compared to base-
line (p<0.05), and this reduction was not affected by addition 
of celecoxib. 
Changes in collagen-induced platelet aggregation are shown 
in Fig. 1B. Celecoxib treatment alone did not affect collagen-
induced platelet aggregation (pretreatment 85.9±15.0% vs. 
post-treatment 76.5±14.4%, p=0.12). ASA or ASA+CPD gr-
oup showed reduced collagen-induced platelet aggregation 
compared to baseline (p<0.05), which was not affected by 
celecoxib. 
The reduction in ADP-induced platelet aggregation by ASA 
(Δ aggregation, Pretreatment inhibition %-Post-treatment in-
hibition %) was not retarded by addition of CCX; rather, it was 
potentiated (9.8±9.2% vs. 30.9±16.8%, p=0.021) (Fig. 2A). The 
reduction in collagen-induced platelet aggregation by aspirin 
was not significantly retarded by addition of celecoxib (ASA gr-
oup 38.6±12.1% vs. ASA+CCX group 29.1±20.9%, p=0.29) 
(Fig. 2A).
We also compared the ‘Δ aggregation’ between ASA+CPD 
and ASA+CPD+CCX groups. The reduction in ADP-induced 
platelet aggregation by ASA+CPD was not significantly af-
fected by addition of celecoxib (ASA+CPD group 31.3±6.9% 
vs. ASA+CPD +CCX group 32.4±12.2%, p=0.83) (Fig. 2B). In-
hibition of collagen-induced platelet aggregation by aspirin 
and clopidogrel was also not affected by addition of celecoxib 
Table 1. Baseline characteristics
CCX ASA ASA+CCX ASA+CPD ASA+CPD+CCX
Number of subjects 8 8 8 8 8
Age (year) 25.3±2.6 23.3±2.6 26.0±2.7 23.6±2.8 24.5±2.6
Male/Female 3/5 7/1 3/5 7/1 3/5
Hb (g/dL) 13.8±1.4 15.6±1.1 14.0±1.7 15.8±1.0 14.5±1.0
Platelet count (×103/mm
3) 262.5±28.0 236.3±47.6 235.4±43.4 258.8±45.9 223.5±33.1
Values of age, hemoglobin, and platelet count are mean±standard deviation. CCX: celecoxib, ASA: aspirin, CPD: clopidogrel, Hb: hemoglobin
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Fig. 1. Platelet aggregation (%) induced by (A) ADP, and (B) collagen. Platelet aggregation was measured on Day 0 (pre-treatment), and 
Day 7 (post-treatment). *p<0.05. ADP: adenosine 5’-diphosphate, CCX: celecoxib, ASA: aspirin, CPD: clopidogrel. Values are means±
standard deviation.   
Fig. 2. Reductions in platelet aggregation (Pretreatment inhibition %-Post-treatment inhibition %) by antiplatelet agents with or without 
addition of celecoxib. A: comparison between aspirin (ASA) and aspirin+celecoxib (ASA+CCX). B: comparison between aspirin+clopi-
dogrel group (ASA+CPD) and aspirin+clopidogrel+celecoxib (ASA+CPD+CCX). Values are means±standard deviation. *p<0.05. ADP: 
adenosine 5’-diphosphate. 
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Fig. 1. Platelet aggregation (%) induced by (A) ADP, and (B) collagen. Platelet aggregation was measured on day 0 (Pre), and day 7 (Post). 
Values are means±standard deviation. *p<0.05. ADP: adenosine 5’-diphosphate, CCX: celecoxib, ASA: aspirin, CPD: clopidogrel, Pre: pre-
treatment, Post: post-treatment.
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(47.6±13.4% vs. 51.6±23.7%, p=0.69) (Fig. 2B). 
Prostacyclin production
Pretreatment mean urine 6-keto PGF1α values adjusted by 
urine creatinine were not different among groups (Fig. 3). 
All groups tended to have decreased adjusted urine 6-keto 
PGF1α levels after administration of study medications com-
pared to pretreatment values. These trends were not statisti-
cally significant except for the ASA+CPD+CCX group (Fig. 
3E) (Pretreatment 296.8±231.4 pg/mg creatinine vs. post-
treatment 102.0±43.1 pg/mg creatinine, p=0.025). When we 
compared the changes in urine 6-keto PGF1α levels (pretreat-
ment value-post-treatment value) (Fig. 4), there were no sig-
nificant differences between ASA and ASA+CCX groups (75.8 
±199.7 pg/mg creatinine vs. 108.8±295.5 pg/mg creatinine, 
p=1.0) or between ASA+CPD and ASA+CPD+CCX groups 
(49.5±406.6 pg/mg creatinine vs. 194.8±219.9 pg/mg creati-
nine, p=0.20) (Fig. 4A). 
Thromboxane production
In all five groups, treatment with anti-platelet agents with 
or without celecoxib showed a tendency towards decreased 
levels of urinary 11-dehydro-TXB2 (Fig. 3). In the ASA+CCX 
group there was a statistically significant decrease in the level 
of urine 11-dehydro-TXB2 after treatment (Fig. 3C) (Pretreat-
ment 409.5±181.6 pg/mg creatinine vs. post-treatment 152.6± 
82.1 pg/mg creatinine, p=0.012). 
The reduction in urine 11-dehydro-TXB2 was more pro-
found after ASA+CCX than after ASA treatment alone (Fig. 
4B) (256.96±213.1 pg/mg creatinine vs. 17.2±114.1 pg/mg cre-
atinine, p=0.005). Reductions in urinary 11-dehydro-TXB2 
were not significantly different between ASA+CPD and ASA+ 
CPD+CCX groups.
Discussion
We demonstrated that celecoxib does not affect the ability 
of aspirin and clopidogrel to inhibit platelet aggregation in-
duced by ADP or by collagen in healthy individuals. Our st-
udy shows that the effect of celecoxib on prostacyclin produc-
tion is not significant when added to a regimen of aspirin and 
clopidogrel. Moreover, celecoxib tended to decrease the level 
of thromboxane production further when given in combina-
tion with aspirin and clopidogrel. No adverse events during 
the study was observed.
Effect of celecoxib on prostacyclin and thromboxane 
metabolism
There has been a concern that COX-2 inhibitors might in-
crease thrombogenicity and are associated with adverse car-
diovascular events. The rationale was that COX-2 inhibitors 
suppress the synthesis of prostacyclin in endothelial cells while 
they cannot inhibit thromboxane A2 formation due to unop-
posed expression of COX-1 in platelets.
14) It was demonstrat-
ed that urinary excretion of 2, 3 dinor-6 keto PGF1α and 6-keto 
PGF1α, which represents prostacyclin biosynthesis, was reduc-
ed by celecoxib at 4-6 hours after dosing, and partially recov-
ered after 12-24 hours.
13) The effect of aspirin and clopidogrel 
on prostacyclin production was assessed in vitro in a previous 
study,
15) where aspirin reduced endothelial production of 6-keto 
PGF1α significantly in a concentration-dependent way, where-
as clopidogrel did not. However, celecoxib did not interfere 
with normal mechanisms of platelet aggregation and hemosta-
sis and did not alter serum thromboxane B2 level in healthy 
adults.
16) 
In our study, prostacyclin production tended to decrease 
in all five groups after treatment. Although it was not statis-
tically significant, prostacyclin production seemed to decrease 
more in the ASA+CCX group than in the ASA group, and 
more in the ASA+CPD+CCX than in the ASA+CPD group. 
But these changes in prostacyclin production were paralleled 
by changes in thromboxane. Our results shows that urinary 
11-dehydro-TXB2 levels were also decreased significantly 
more in the ASA+CCX group than in the ASA only group, and 
tended to decrease more in the ASA+CPD+CCX group com-
pared to the ASA+CPD group. Together, these results suggest 
that celecoxib as a COX-2 inhibitor has a neutral effect on pl-
atelet aggregation since it has mild inhibitory effects not only 
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on prostacyclin production but also on thromboxane produc-
tion, thus not changing the balance of prostacyclin and throm-
boxane.
No effect of celecoxib on aspirin’s anti-platelet 
action
In this study, aspirin inhibited ADP-induced platelet aggre-
gation and collagen-induced platelet aggregation by 13% and 
55% respectively. This result is consistent with a previous st-
udy that reported values of 14% and 50%.
17) We confirmed 
that celecoxib did not affect the platelet aggregation response 
to collagen in healthy volunteers receiving aspirin as Wilner 
et al.
18) previously reported. Also in patients who were taking 
aspirin and had both osteoarthritis and ischemic heart disease, 
celecoxib, unlike ibuprofen, did not influence aspirin’s action 
to irreversibly inactivate platelet COX-1.
19) 
Potential beneficial effects of celecoxib on the
vasculature
In addition, celecoxib is known to have COX-independent 
biological effects. We previously reported that celecoxib in 
animal studies inhibits neointimal hyperplasia after balloon 
injury by blocking Akt signaling.
20) Celecoxib also decreases 
inflammatory responses and neointimal hyperplasia, possi-
bly through inhibition of MCP-1 expression.
21) It also sup-
pressed aortic endothelial cell tissue factor expression, lead-
ing to prevention of thrombus formation in the vasculature, 
which was observed for celecoxib but not for other COX-2 
inhibitors.
22) 
No thrombotic risk of celecoxib under dual anti-plate-
let agents
In the current study, we evaluated the effect of dual anti-
platelet therapy (aspirin and clopidogrel) on platelet aggrega-
tion and whether celecoxib affects the antiplatelet aggrega-
tion activity of aspirin and clopidogrel. Clopidogrel has a po-
tent anti-thrombotic action by blocking P2Y12, a platelet ADP 
receptor, and also inhibits platelet aggregation induced by 
collagen.
15)23) 
In our study, we demonstrated a significant additional in-
hibitory effect of clopidogrel on both ADP- and collagen-in-
duced platelet aggregation when added to aspirin. More im-
portantly, we observed that the enhanced antiplatelet effect 
of dual antiplatelet therapy compared to aspirin alone is not 
altered by concomitant celecoxib use. This result is consis-
tent with our previous prospective randomized clinical trial,
3) 
where additional of celecoxib treatment for 6 months after 
coronary stenting significantly reduced late loss of the stent-
ed segment and the target lesion revascularization rate without 
any increase in adverse thrombotic events. It is noteworthy that 
all patients in this trial were taking both aspirin and clopido-
grel for more than six months after stenting.
NSAIDs class adverse effects
Despite these results indicating that celecoxib does not at-
tenuate the antiplatelet action of aspirin and clopidogrel, and 
that celecoxib might even have a favorable effect on the car-
diovascular system, several clinical studies have questioned the 
safety of celecoxib treatment for the cardiovascular system. 
The Cross Trial Safety Analysis which assessed cardiovascu-
lar risk based on >16,000 patient-years of follow-up from six 
randomized placebocontrolled trials including APC,
24) Pre-
SAP, and ADAPT concluded that celecoxib increases the num-
ber of adverse cardiovascular events. But such risk may not be 
celecoxib-specific. Rather, it may that the increased risk is as-
sociated with the entire class of NSAIDs. The mechanism of 
class risk of NSAIDs may be multi-factorial, i.e., induction 
of blood pressure elevation and platelet aggregability, etc. 
Actually, celecoxib’s cardiovascular risk has been reported to 
be relatively low compared with other NSAIDs.
25-27) Addi-
tion of celecoxib to patients who take dual anti-platelet agents 
due to coronary stenting, do not appear to be associated with 
thrombotic risk.
Limitations
The current study recruited young healthy volunteers in-
stead of old patients at risk for developing cardiovascular 
disease. In the setting of atherosclerosis, suppression of PGI2 
production in endothelial cells by celecoxib is pronounced, 
since COX-2 plays a greater role as a source of PGI2.
28)29) As a 
result, celecoxib might have a more profound effect on pros-
tanoid balance under atherosclerotic conditions, promoting 
platelet-dependent thrombosis.
30) 
The number of volunteers allocated to each treatment group 
was rather small. However, previous reports evaluating effects 
of celecoxib on antiplatelet activity and prostanoids had simi-
lar numbers of subjects. And results of platelet function tests in 
this study were consistent with those from previous studies. 
Conclusion
Celecoxib does not interfere with the antiplatelet action of 
dual antiplatelet therapy, and it does not affect the balance of 
prostacyclin and thromboxane production. Recent evidence 
suggests that celecoxib may increase cardiovascular events in 
high risk patients and that aspirin may not be protective. Since 
patients with coronary artery stenting take aspirin and clopi-
dogrel together, and some of them take it indefinitely, our study 
results are worth consideration. Celecoxib can be administered 
safely in these patients during coverage of dual antiplatelet th-
erapy. Current warnings for celecoxib now mandate larger cli-
nical trials that evaluate the safety of celecoxib during dual an-
tiplatelet therapy following stenting.
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